Clinical Trial Update: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study [Phase 3]

View source ↗

Summary

The EINSTEIN PE Phase 3 trial evaluated rivaroxaban for the treatment of acute symptomatic pulmonary embolism, with results posted in January 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Pulmonary Embolism | Phase 3 | Status: COMPLETED | Results posted: 2013-01-24